New drug duo targets hard-to-treat lung cancer

NCT ID NCT04250545

First seen Dec 10, 2025 · Last updated May 15, 2026 · Updated 19 times

Summary

This early-phase trial tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goals are to find the safest dose and see if the combination can shrink tumors or slow the disease. About 22 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • City of Hope at Irvine Lennar

    Irvine, California, 92618, United States

  • Keck Medicine of USC Koreatown

    Los Angeles, California, 90020, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.